Nicola Tyson

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Ronald van Vollenhoven, Paul Emery, Clifton O. Bingham et al. · Annals of the Rheumatic Diseases · 2012 · 391 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

John C. Byrd, Joseph M. Flynn, Thomas J. Kipps et al. · Blood · 2015 · 85 citations · Full text

Life Sciences, Immunology, Oncology +11

Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.

Joseph M. Flynn, John C. Byrd, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2014 · 21 citations

Medicine, Hematology, Pharmacology +11

Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study

Stephan Stilgenbauer, Osman İlhan, Darius Woszczyk et al. · Blood · 2015 · 15 citations

Medicine, Oncology, Pharmacology +10